[Hormone therapy in invasive breast cancer : update 2016]

Invasive breast cancer is the most common malignancy in women in industrialized countries. Three-quarters of breast cancers express estrogen and/or progesterone receptors and are considered endocrine-sensitive. Endocrine therapy reduces the risk of loco-regional, contralateral and distant recurrence. The management has become more complex with estrogen receptor inhibitors, aromatase inhibitors and ovarian function suppression. The choice of the regimen and its duration depend on the age, the menopausal status of the patient, her co-morbidities, the risk of cancer relapse and the tolerance. We summarize here the recent modifications of the endocrine therapy in early and advanced stage breast cancer.